Navigation Links
New Breast Imaging Technology Targets Hard-to-Detect Cancers
Date:12/2/2008

CHICAGO, Dec. 3 /PRNewswire-USNewswire/ -- Breast-specific gamma imaging (BSGI) is effective in the detection of cancers not found on mammograms or by clinical exam, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

"BSGI can identify the most difficult to detect breast cancer-invasive lobular carcinoma," said lead author Rachel F. Brem, M.D., professor of radiology and director of the Breast Imaging and Interventional Center at The George Washington University Medical Center in Washington, D.C. "It also can help us detect additional lesions of all types of breast cancer in women whose mammograms show only one suspicious lesion."

Breast cancer affects more women than any other non-skin cancer and, according to the American Cancer Society, accounts for more than 40,000 deaths annually in the U.S. Most experts agree that the best way to decrease breast cancer mortality is through early detection using mammography and clinical breast exam. However, some cancers are difficult to detect with mammography and clinical exam, particularly in the earliest stage when treatment is most effective.

While mammography findings are characterized by the difference in appearance between normal and suspicious breast tissue, BSGI findings are based on how cancerous cells function.

"It is this physiological approach to breast cancer diagnosis that allows for improved cancer detection," Dr. Brem said.

BSGI is an emerging molecular imaging technology using a high-resolution gamma camera that allows for imaging with very mild compression of the breast along with an injection of a low-dose nuclear material called a radiotracer, which is absorbed by the cells. Because cancerous cells have a higher rate of metabolic activity, the tracer is taken up by these cells at a higher level than in normal cells.

Dr. Brem and colleagues reviewed the records of 159 women with at least one suspicious or cancerous lesion found by mammography or physical exam, who had undergone BSGI to determine if additional lesions were present.

BSGI results showed an additional suspicious lesion missed by mammography and physical exam in 46 (29 percent) of the women. In 14 (36 percent) of the 39 women who underwent biopsy, the newly discovered lesions were cancerous.

"The data suggest that BSGI allows for the diagnosis of more and earlier breast cancers," Dr. Brem said.

Dr. Brem pointed out that BSGI is not meant to replace mammography, but to be used as an adjunct to mammography. "It is an excellent tool for locating difficult-to-detect cancers and for screening high-risk women who have normal mammograms and physical examination," she said.

    AT A GLANCE
    -- Breast-specific gamma imaging (BSGI) is an effective method of
    detecting hard-to-find breast cancer.
    -- BSGI identifies cancers not visible on mammograms and not found by
    clinical examination.
    -- BSGI findings are based on the metabolic activity of cancer cells.

Disclosure: Dr. Brem is on the board of directors of iCAD, Inc., a board member of Dilon Technologies LLC and a consultant for Orbotech Ltd.

Note: Copies of RSNA 2008 news releases and electronic images will be available online at RSNA.org/press08 beginning Monday, Dec. 1.

RSNA is an association of more than 42,000 radiologists, radiation oncologists, medical physicists and related scientists committed to excellence in patient care through education and research. The Society is based in Oak Brook, Ill. (RSNA.org)

Editor's note: The data in these releases may differ from those in the printed abstract and those actually presented at the meeting, as researchers continue to update their data right up until the meeting. To ensure you are using the most up-to-date information, please call the RSNA Newsroom at 1-312- 949-3233.

For patient-friendly information on breast imaging, visit RadiologyInfo.org.


'/>"/>
SOURCE Radiological Society of North America (RSNA)
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Mammography Technology Effective in Detecting Breast Cancer
2. Siemens Introduces New Standard of Care for Breast Ultrasound
3. Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
4. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
5. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
6. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
7. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
8. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
9. Young Women Diagnosed with Early-Stage Breast Cancer More Likely to Die than Older Women
10. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
11. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)...  West Pharmaceutical Services, Inc. (NYSE: WST ... 2017 and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, ... Net sales at constant currency (organic) grew by 3.9%. ... compared to $0.60 in the prior-year quarter. Second-quarter 2017 ...
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
(Date:7/26/2017)... 26, 2017 The Galien Foundation announced ... USA Award Nominees. Counted among the global ... recognizes outstanding biomedical and technology product achievement that improves the ... qualify, each candidate must be U.S. Food and Drug Administration ... demonstrate tremendous potential to impact human health. Sales data are ...
Breaking Medicine Technology:
(Date:7/27/2017)... Plano, TX (PRWEB) , ... July 27, 2017 ... ... technology and outsourced services, announces the internal promotion of Elrene Clinkscales to Vice ... Operations – Claims & Remittance Management, reporting to Derek Morkel, chief executive officer ...
(Date:7/27/2017)... ... 2017 , ... Team Novo Nordisk, the world’s first all-diabetes professional cycling team, ... a stagiaire for the remainder of the 2017 season. One of our best development ... Tour of Utah. , “Every season we are excited to move an athlete from ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley D. Beall, ... in drug therapy for patients living with relapsing and primary multiple sclerosis that ... cell targeted therapy that has been proven to significantly reduce signs of disease ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we thought there ... Jose, Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending MAGNETIC/ LOCK ... In doing so, it offers an effective alternative to traditional braces. As a result, ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be ... for patients to schedule an appointment online in real time,” said Keith English, LocalMed ... Smiles provider directory will bring more Six Month Smiles patients to their providers.” , ...
Breaking Medicine News(10 mins):